patents

First Opinion By Othman Laraki

Proposed patent legislation would block research, stifle innovation, and harm patients

Pharmalot By Ed Silverman

FTC says pay-to-delay cases fell, prompting trade group to argue legislation isn’t needed

Pharmalot By Ed Silverman

Baltimore sues a J&J unit over ‘sham’ patent litigation to extend its monopoly on a cancer drug

Pharmalot By Ed Silverman

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

Pharmalot By Ed Silverman

Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

Pharmalot By Ed Silverman

Pharmalittle: Allergan depression drug fails three trials; Vertex CEO appears before Parliament

Pharmalot By Ed Silverman

Bristol-Myers faces growing opposition to its Celgene deal. Here’s what the wags are saying

Pharma By Ed Silverman and Matthew Herper

Regeneron CEO: ‘We need a carrot-and-stick system’ to balance pricing and innovation

Pharmalot By Ed Silverman

Pharmalittle: Drug makers to raise prices in January; Novartis names a new oncology chief, again

Pharmalot By Ed Silverman

Trump administration report would preclude reclaiming patents as a way to lower drug prices

Pharmalot By Ed Silverman

Pharmalittle: Retail drug spending in the U.S. fell last year; Democrats eye patents to lower drug prices

Pharmalot By Ed Silverman

Pharmalittle: AbbVie cancer program’s setback; Amazon hires a pharmacy expert

Pharmalot By Ed Silverman

Boehringer Ingelheim abandons biosimilar sales outside the U.S.

Pharmalot By Ed Silverman

Pharmalittle: D.C. law firms prep pharma for a Democratic house; Allergan loses another battle over Restasis patent deal

Pharmalot By Ed Silverman

Pharmalittle: Trump hiring restrictions hurt FDA; Purdue family member has patent for addiction treatment

Pharmalot By Ed Silverman

U.N. global declaration on TB passes key hurdle as U.S. and others reach a compromise

Pharmalot By Ed Silverman

Allergan is urged to split CEO and chairman jobs by ‘disappointed’ hedge funds

Pharmalot By Ed Silverman

Pharmalittle: Amgen migraine drug costs less than expected; J&J halts development on Alzheimer’s drug

Pharmalot By Ed Silverman

With a push from pharma, U.S. Trade Rep pressure on Colombia starts to take hold

Pharmalot By Ed Silverman

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

Pharmalot By Ed Silverman

NIH is urged to probe Aegerion patents for failing to disclose federal funding

Pharmalot By Ed Silverman

Tens of millions of people continue to lack access to hepatitis C medicines

Pharmalot By Ed Silverman

HHS is urged to investigate a Gilead hepatitis C patent for failing to disclose federal funding

Pharmalot By Ed Silverman

Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries

Pharmalot By Ed Silverman

Pharmalittle: Will Jeff Sessions really go after opioid makers? Mylan pursues a biosimilar Botox